Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
GlucoTrack ( (GCTK) ) just unveiled an announcement.
On January 21, 2025, Glucotrack announced it received ISO13485:2016 certification from the British Standards Institute, marking a significant milestone for the company’s continuous blood glucose monitor (CBGM). This certification underscores Glucotrack’s commitment to quality and regulatory excellence, aligning with international standards for medical devices and potentially strengthening its market position.
More about GlucoTrack
Glucotrack, Inc. is a medical technology company focused on designing, developing, and commercializing novel technologies for people with diabetes. The company is currently developing a long-term implantable continuous blood glucose monitoring system designed to measure blood glucose levels with a sensor longevity of three years, without an on-body wearable component and minimal calibration.
YTD Price Performance: -73.50%
Average Trading Volume: 31,615,634
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.36M
Find detailed analytics on GCTK stock on TipRanks’ Stock Analysis page.
